Jul 17, 2017
The 6th International Congress on Neuropathic Pain took place June 15-18 in Gothenburg, on the west coast of Sweden. Eight hundred participants from all over the world arrived at the Swedish Exhibition and Congress Center, one of the five largest venues in Europe. In addition to high-quality lectures covering the wide spectrum of neuropathic pain, there was also an opportunity to experience the famous white nights of Scandinavia.
The keynote lecture, named in honor of Dr. J. Edmond Charlton, a founding member of NeuPSIG, was delivered by Professor Ralf Baron. The theme of his award lecture was individualized pain therapy based on phenotyping. Topics of the other plenary lectures ranged from optigenetics and the pathogenetic role of inflammation to the genetics and impact of neuropathic pain, not forgetting the clinical pearls (assessment and new treatments of neuropathic pain) and specific pain syndromes (burning mouth and neuropathic itch).
For the first time in NeuPSIG’s history, the program featured a plenary debate, in which professors Christoph Maier and Steve Bruehl, entertainingly battled over the diagnostic issues of CRPS.
Altogether, 28 workshops provided up-to-date knowledge about post-traumatic trigeminal neuropathy, advances in spinal cord stimulation, conditioned pain modulation, small fiber neuropathy, the increasing importance of ion channels, pain in immune-mediated neurological diseases, genetic and epigenetic regulation of neuropathic pain, and cancer chemotherapy-induced peripheral neuropathy, among many other thought-provoking and important topics.
The Best Poster Award was given to Dr. Greg Weir (UK). He is from Professor David Bennett’s research group, and the title of his acclaimed and very interesting poster was "Using an engineered GluCl channel to silence sensory neurons and treat neuropathic pain at the source." Congratulations, Greg!
As a chair of the scientific committee, I would like to extend my gratitude to all members of the committee: You all contributed greatly to the success of the Congress.
In addition, for those of you who would like to experience the highlights of the meeting or review the workshop presentations you were unable to attend, Pfizer has recorded most of the workshops and plenary lectures for which approval was given by the speakers. These sessions will be available for viewing on Pfizer’s educational website and later also on IASP’s. Congress delegates will soon be informed of the availability of the educational material and where to find it.
-- Aki Hietaharju, chair, NeuPSIG Scientific Committee